RDHomo sapiens (Human)Cancer cell line
Also known as: R D, RD-2, RD 2, 130T, 130-T, 130 T, TE-32, TE 32, TE32, TE 32.T, Te 32.T
RD Cell Line
Quick Overview
RD is a human rhabdomyosarcoma cell line used in cancer research.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_1649 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Pelvis, muscle[UBERON:UBERON_0001325] |
Donor Information
| Age | 7 |
|---|---|
| Age Category | Pediatric |
| Sex | Female |
| Race | caucasian |
Disease Information
| Disease | Embryonal rhabdomyosarcoma |
|---|---|
| Lineage | Soft Tissue |
| Subtype | Embryonal Rhabdomyosarcoma |
| OncoTree Code | ERMS |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000169_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | NRAS | p.Gln61His (c.183A>T) | Unspecified | - | PubMed=26214590 |
| MutationSimple | TP53 | p.Arg248Trp (c.742C>T) | Homozygous | Somatic mutation acquired during proliferation | from parent cell line VCaP |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Surfaceome profiling of cell lines and patient-derived xenografts confirm FGFR4, NCAM1, CD276, and highlight AGRL2, JAM3, and L1CAM as surface targets for rhabdomyosarcoma.
Sala R., Heller M., Rossler J., Bernasconi M.
Int. J. Mol. Sci. 24:2601.1-2601.28(2023).
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
Sellers W.R., Gygi S.P.
Cell 180:387-402.e16(2020).
Proteomic profiling of rhabdomyosarcoma-derived exosomes yield insights into their functional role in paracrine signaling.
Diab-Assaf M., Saab R., Ghayad S.E.
J. Proteome Res. 18:3567-3579(2019).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
Tissue typing of cells in culture. III. HLA antigens of established human cell lines. Attempts at typing by the mixed hemadsorption technique.
Espmark J.A., Ahlqvist-Roth L., Sarne L., Persson A.
Tissue Antigens 11:279-286(1978).
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
Fogh J., Fogh J.M., Orfeo T.
J. Natl. Cancer Inst. 59:221-226(1977).
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
Fogh J., Wright W.C., Loveless J.D.
J. Natl. Cancer Inst. 58:209-214(1977).
Reduced metastatic ability of in vitro differentiated human rhabdomyosarcoma cells.
Nanni P.
Invasion Metastasis 11:116-124(1991).
Mutation of the p53 gene in human soft tissue sarcomas: association with abnormalities of the RB1 gene.
Fletcher C.D.M., Ball A.B.S., Thomas M., Gusterson B.A., Cooper C.S.
Oncogene 5:1297-1301(1990).
In vitro purging of human rhabdomyosarcoma cells using 4-hydroperoxycyclophosphamide.
Ozkaynak M.F., Nolta J., Parkman R.
Cancer Res. 50:1455-1458(1990).
N-ras gene activation in the RD human rhabdomyosarcoma cell line.";
Chardin P., Yeramian P.D., Madaule P., Tavitian A.
Int. J. Cancer 35:647-652(1985).
Cultivation in vitro of cells derived from a human rhabdomyosarcoma.
Gardner M.B.
Cancer 24:520-526(1969).
Polymorphic enzyme analysis of cultured human tumor cell lines.";
Dracopoli N.C., Fogh J.
J. Natl. Cancer Inst. 70:469-476(1983).
Development of resistance to vincristine in a childhood rhabdomyosarcoma growing in immune-deprived mice.
Houghton J.A., Houghton P.J., Brodeur G.M., Green A.A.
Int. J. Cancer 28:409-415(1981).
Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma.
Rauscher F.J. 3rd, Emanuel B.S., Rovera G., Barr F.G.
Nat. Genet. 5:230-235(1993).
Deficiency in rhabdomyosarcomas of a factor required for MyoD activity and myogenesis.
Tapscott S.J., Thayer M.J., Weintraub H.M.
Science 259:1450-1453(1993).
Rhabdomyosarcoma rho(0) cells: isolation and characterization of a mitochondrial DNA depleted cell line with 'muscle-like' properties.
Vergani L., Prescott A.R., Holt I.J.
Neuromuscul. Disord. 10:454-459(2000).
Mutations of the BRAF gene in human cancer.";
Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Nature 417:949-954(2002).
Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies.
Hongo T., Taki T., Ogasawara M., Shimada A., Hayashi Y.
Genes Chromosomes Cancer 45:583-591(2006).
Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas.
Olshen A.B., Barr F.G., Ladanyi M.
J. Pathol. 212:143-151(2007).
Identification of side population cells (stem-like cell population) in pediatric solid tumor cell lines.
Hayashi Y.
J. Pediatr. Surg. 42:2040-2045(2007).
Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development.
Pritchard-Jones K., Kool M., Shipley J.M.
Genes Chromosomes Cancer 48:455-467(2009).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.
Reynolds C.P.
Pediatr. Blood Cancer 56:239-249(2011).
Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis.
Belyea B.C., Naini S., Bentley R.C., Linardic C.M.
Clin. Cancer Res. 17:7324-7336(2011).
Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.
Borsu L., Barr F.G., Ladanyi M.
Clin. Cancer Res. 18:748-757(2012).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
miR-206 integrates multiple components of differentiation pathways to control the transition from growth to differentiation in rhabdomyosarcoma cells.
MacQuarrie K.L., Yao Z.-Z., Young J.M., Cao Y., Tapscott S.J.
Skelet. Muscle 2:7.1-7.14(2012).
Characterization of genetic lesions in rhabdomyosarcoma using a high-density single nucleotide polymorphism array.
Ogawa S.
Cancer Sci. 104:856-864(2013).
Cetuximab promotes anticancer drug toxicity in rhabdomyosarcomas with EGFR amplification in vitro.
Kitagawa Y., Morikawa Y., Kuroda T.
Oncol. Rep. 30:1081-1086(2013).
Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls.
Linardic C.M.
Front. Oncol. 3:183.1-183.12(2013).
A mass spectrometric-derived cell surface protein atlas.";
Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.
PLoS ONE 10:E0121314-E0121314(2015).
Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression.
Harris E., Monks A., Morris J.
Mol. Cancer Ther. 14:2452-2462(2015).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).